Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dr. Reddy’s wins generic Zantac approval

This article was originally published in The Tan Sheet

Executive Summary

FDA approves Dr. Reddy's Laboratories abbreviated new drug application to manufacture and market generic OTC versions of ranitidine 150 mg tablets acid indigestion treatment (GlaxoSmithKline's Zantac), Dr. Reddy's announces Sept. 13. The Hyderabad, India-based drug firm says the approval marks its first U.S. drug approval since it unveiled plans in May to launch a store-brand OTC business unit in the country. The firm is set to expand its OTC product portfolio and additional product introductions in the coming months which will include Rx switches and select OTC monograph products, the firm's North American Generics President Mark Hartman said...

You may also be interested in...



Perrigo's Zantac 150 Generic Marks First Approval From Remediated Plant

Perrigo will launch private-label equivalents of OTC heartburn reliever Zantac 150 this summer.

FDA in India

HHS Secretary Michael Leavitt and FDA Commissioner Andrew von Eschenbach are organizing teams to help advise the Indian government in creating its equivalent to FDA, Leavitt says Jan. 7 in a post to his blog. Leavitt offered the Indian Minister of Health and Family Welfare, Anbumani Ramadoss, technical assistance and discussed food and drug safety, he says. In September 2007, von Eschenbach worked with Chinese officials to finalize a memorandum on food, drug and medical device safety (1"The Tan Sheet" Sept. 24, 2007, In Brief)...

Keeping Track: US FDA Clears Esperion’s Nexletol, Baudax’ Anjeso, Agile’s Twirla

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Topics

UsernamePublicRestriction

Register

PS100929

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel